News & Updates

In the new analysis of the REGENERATE trial, the FXR* agonist obeticholic acid (OCA) was generally well tolerated and demonstrated a favourable safety profile in patients with nonalcoholic steatohepatitis (NASH).

Diabetes mellitus (DM) and obesity are two of the most prevalent chronic health conditions worldwide, affecting millions of individuals globally.1,2 As the landscape of diabetes therapy continues to evolve, it is becoming increasingly clear that a one-size-fits-all approach is no longer sufficient. By considering a range of factors beyond just glucose control, healthcare providers can provide more effective, personalized care that results in better outcomes for patients with diabetes. 

For individuals with increased projected risk of probable dementia or amnestic mild cognitive impairment (MCI) who are prescribed antihypertensive treatment, intensive systolic blood pressure (SBP) lowering confers greater cognitive benefits than standard treatment, according to a secondary analysis of the SPRINT trial.

Treatment with clevidipine in patients undergoing cardiac surgery leads to better perioperative blood pressure (BP) control relative to nicardipine, with a slight rise in cost and no significant difference in safety outcomes, a study has found.

Adding glucagon-like peptide-1 receptor agonists (GLP1RA) onto metformin, sulfonylurea, or insulin treatment alone or in combination appears to reduce the incidence of major adverse cardiac events (MACE) and heart failure (HF) hospitalization relative to treatment with dipeptidyl peptidase-4 inhibitors (DPP4i), suggests a study.

Use of amiodarone in older patients with atrial fibrillation (AF) who are being treated with apixaban or rivaroxaban results in a higher risk of bleeding-related hospitalizations compared with the use of flecainide or sotalol, reports a study.

Administration of maternal influenza vaccine during the first- or second-trimester of pregnancy reduces the risk of influenza-like illness (ILI) in the offspring, according to a study presented at ESPID 2023.